Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 200

1.

Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

Zhong L, Pon V, Srinivas S, Nguyen N, Frear M, Kwon S, Gong C, Malmstrom R, Wilson L.

PLoS One. 2013 May 22;8(5):e64275. doi: 10.1371/journal.pone.0064275. Print 2013.

PMID:
23717582
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R.

Health Technol Assess. 2007 Jan;11(2):iii-iv, xv-xviii, 1-179. Review.

PMID:
17181985
[PubMed - indexed for MEDLINE]
Free Article
3.

Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.

Kearns B, Lloyd Jones M, Stevenson M, Littlewood C.

Pharmacoeconomics. 2013 Jun;31(6):479-88. doi: 10.1007/s40273-013-0050-9. Review.

PMID:
23580356
[PubMed - indexed for MEDLINE]
4.

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.

Paller CJ, Antonarakis ES.

Drug Des Devel Ther. 2011 Mar 10;5:117-24. doi: 10.2147/DDDT.S13029. Review. Erratum in: Drug Des Devel Ther. 2011;5:183.

PMID:
21448449
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.

Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D.

Prostate. 2014 Apr;74(4):433-40. doi: 10.1002/pros.22765. Epub 2013 Dec 11.

PMID:
24338986
[PubMed - indexed for MEDLINE]
6.

Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Sorensen S, Ellis L, Wu Y, Hutchins V, Linnehan JE, Senbetta M.

J Manag Care Pharm. 2013 Nov-Dec;19(9):799-808.

PMID:
24156649
[PubMed - indexed for MEDLINE]
Free Article
7.

New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?

Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, Yu D, Srinivas S.

J Oncol Pharm Pract. 2013 Nov 14. [Epub ahead of print]

PMID:
24243919
[PubMed - as supplied by publisher]
8.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

PMID:
20888992
[PubMed - indexed for MEDLINE]
9.

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.

Sartor AO.

J Hematol Oncol. 2011 Apr 23;4:18. doi: 10.1186/1756-8722-4-18. Review.

PMID:
21513551
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.

Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators.

Eur J Cancer. 2013 Nov;49(17):3648-57. doi: 10.1016/j.ejca.2013.07.144. Epub 2013 Aug 22.

PMID:
23973186
[PubMed - indexed for MEDLINE]
11.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

PMID:
16545208
[PubMed - indexed for MEDLINE]
Free Article
12.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
[PubMed - indexed for MEDLINE]
13.

[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].

Lheureux S, Joly F.

Bull Cancer. 2012 Sep;99(9):875-80. doi: 10.1684/bdc.2012.1617. French.

PMID:
22877855
[PubMed - indexed for MEDLINE]
14.

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.

Payne H, Bahl A, Mason M, Troup J, De Bono J.

BJU Int. 2012 Sep;110(5):658-67. doi: 10.1111/j.1464-410X.2011.10886.x. Epub 2012 Mar 19.

PMID:
22429837
[PubMed - indexed for MEDLINE]
15.

New treatment options for castration-resistant prostate cancer.

Simondsen K, Kolesar J.

Am J Health Syst Pharm. 2013 May 15;70(10):856-65. doi: 10.2146/ajhp110586. Review.

PMID:
23640346
[PubMed - indexed for MEDLINE]
16.

Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.

Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):406-30. doi: 10.1016/j.clon.2013.03.002. Epub 2013 Apr 12. Review.

PMID:
23587782
[PubMed - indexed for MEDLINE]
17.

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J.

Cancer Treat Rev. 2014 Feb;40(1):170-7. doi: 10.1016/j.ctrv.2013.06.008. Epub 2013 Aug 16. Review.

PMID:
23958310
[PubMed - indexed for MEDLINE]
Free Article
18.

Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.

Gallardo E, Arranz JÁ, Maroto JP, León LÁ, Bellmunt J.

Crit Rev Oncol Hematol. 2013 Nov;88(2):357-67. doi: 10.1016/j.critrevonc.2013.06.008. Epub 2013 Jul 16. Review.

PMID:
23867574
[PubMed - indexed for MEDLINE]
19.

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.

Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campennì GM, Palazzo A, Cortesi E.

Cancer Biol Ther. 2012 Sep;13(11):1001-8. doi: 10.4161/cbt.21188. Epub 2012 Jul 24. Review.

PMID:
22825325
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.

Benedict A, Cameron DA, Corson H, Jones SE.

Pharmacoeconomics. 2009;27(10):847-59. doi: 10.2165/10899510-000000000-00000.

PMID:
19803539
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk